The world has been and continues to unite to “flatten the curve” of the outbreak of COVID-19. Exact Imaging began its support of this critical initiative on Friday March 13, 2020. We have implemented the following measures to ensure we protect and support our customers, employees, suppliers, and business:
COVID-19 is a collective challenge facing our world, and Exact Imaging joins all of you in meeting the challenge head-on. Continue social distancing, stay safe, and keep moving. This too shall pass.
Our very best to you and your families from all of us on the Exact Imaging Team.
About Exact Imaging
Exact Imaging (www.exactimaging.com) is the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging’s ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and is an extension of the current urological workflow. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and specifically target biopsies at those areas. For those cases where MRI might assist, the FusionVu™ micro-US/MRI fusion application operates on the ExactVu micro-ultrasound platform and facilitates fast, simple MRI fusion-based targeting with the guidance of the micro-ultrasound system’s 70-micron real-time resolution. The ExactVu micro-ultrasound system including the FusionVu application has received regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)), and Canada (Health Canada medical device license).